LGVN - Longeveron's Alzheimer's Candidate Meets Safety Goal In Mid-Stage Study | Benzinga
Longeveron Inc (NASDAQ: LGVN) announced topline results from the Phase 2a trial of its investigational product Lomecel-B for mild Alzheimer's disease.
An estimated 6.7 million Americans are living with Alzheimer's disease. Of the total U.S. population, about 1 in 9 people aged 65 and older has Alzheimer's disease.
The primary endpoint of safety was met based on statistical and medical assessment. One Serious Adverse Event (SAE) was reported on each Lomecel-B ...